Company profile
Arrowhead Pharmaceuticals, Inc.
NASDAQ: ARWR · Healthcare · Biotechnology
#170 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
76B+FH 75DQ 80GM 61SS 91
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$669.5M
Rev growth YoY (TTM)
+16.8%
Net income (FY)
-$1.6M
Employees
711
as of 2026-08-05
Market cap
$12.6B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$829.4M$829.4M2025
Net income-$1.6M-$1.6M2025
Operating income$98.3M$98.3M2025
Total assets$1.4B$1.4B2025
Equity$466.1M$466.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Arrowhead Pharmaceuticals, Inc.’s revenue?
Arrowhead Pharmaceuticals, Inc. booked $829.4M in FY2025 revenue, growing 23258% year over year — faster than 100% of Healthcare companies we track, at a -0.2% net margin.
Peers · Healthcare
Innovage Holding Corp.68BVarex Imaging Corporation67BVerano Holdings Corp59CMyriad Genetics, Inc.67BOrthofix Medical Inc.75B+Tilray Brands, Inc.52DNeighbors
Los Angeles →Key facts
CEOChristopher R. Anzalone
SectorHealthcare
IndustryBiotechnology
HeadquartersPasadena, CA
ExchangeNASDAQ: ARWR
Employees711
IPO date1993-12-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.